82 / 89
82
cyclophosphamide and methylprednizolone in
patients with systemic sclerosis and interstitial
lung disease. Rheumatol Int 2007;27:357-61.
102.
Domiciano DS, Bonfá E, Borges CT, Kairalla
RA, Capelozzi VL, Parra E, et al. A long-term
prospective randomized controlled study of
non-specific interstitial pneumonia (NSIP)
treatment in scleroderma. Clin Rheumatol
2011;30:223-9.
103.
Nannini C, West CP, Erwin PJ, Matteson EL.
Effects of cyclophosphamide on pulmonary
function in patients with scleroderma and
interstitial lung disease: a systematic review
and meta-analysis of randomized controlled
trials and observational prospective cohort
studies. Arthritis Res Ther 2008;10:R124.
104.
Tochimoto A, Kawaguchi Y, Hara M, Tateishi
M, Fukasawa C, Takagi K, et al. Efficacy and
safety of intravenous cyclophosphamide pulse
therapy with oral prednisolone in the
treatment of interstitial lung disease with
systemic sclerosis: 4-year follow-up. Mod
Rheumatol 2011;21:296-301.
105.
Seibold JR, Denton CP, Furst DE, Guillevin L,
Rubin LJ, Wells A, et al. Randomized,
prospective,
placebo-controlled
trial
of
bosentan in interstitial lung disease secondary
to systemic sclerosis. Arthritis Rheum
2010;62:2101-8.
106.
Nithyanova SI, Brough GM, Black CM, Denton
CP. Mycophenolate mofetil in diffuse